Item 5.07. Submission of Matters to a Vote of Security Holders.






At Cyclerion Therapeutics, Inc.'s ("Cyclerion" or the "Company") annual meeting
of stockholders held on June 16, 2020, as contemplated by the Company's
definitive proxy material for the meeting, certain matters were submitted to a
vote of stockholders. The following tables summarize the results of voting with
respect to each matter:



1. Election of Directors:



                                                                          Broker
                               For           Against      Withheld       Non-Votes
Kevin Churchwell, M.D.       17,441,940           0         12,954        2,236,855
George Conrades              16,805,918           0         648,976       2,236,855
Marsha Fanucci               17,392,164           0         62,730        2,236,855
Peter M. Hecht, Ph.D.        17,444,180           0         10,714        2,236,855
Ole Isacson, M.D., Ph.D.     17,440,840           0         14,054        2,236,855
Stephen Lovell               17,444,121           0         10,773        2,236,855
Terrance McGuire             17,401,733           0         53,161        2,236,855
Michael Mendelsohn, M.D.     17,400,084           0         54,810        2,236,855
Amy Schulman                 17,440,634           0         14,260        2,236,855

2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020:





   For       Against   Abstain
19,675,633   12,406     3,710

Item 7.01. Regulation FD Disclosure.

On June 18, 2020, the Company issued a press release announcing that it will host a webcast investor event on July 9, 2020 from 8:15 a.m. to 9:30 a.m. Eastern Time. The Company also announced that dosing has been completed in the ongoing IW-6463 translational pharmacology clinical study. Topline study data are expected in late summer 2020. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference into this Current Report on Form 8-K.

This webcast event will focus on IW-6463, the Company's investigational, orally administered, once-daily CNS-penetrant sGC stimulator designed for the treatment of serious CNS diseases. Cyclerion's clinical and scientific leaders will discuss:

· Potential to harness the nitric oxide/sGC system for treating serious CNS

diseases

· IW-6463 preclinical and Phase 1 clinical study data

· Design of the ongoing IW-6463 translational pharmacology clinical study

· Anticipated development directions for our potential CNS therapies

To join the live webcast, please visit the "Investors and Media" section of the Cyclerion website at www.cyclerion.com at least 15 minutes prior to the start of the event.

A webcast replay will be available on the Cyclerion website beginning approximately two hours after the event and will be archived for 21 days.





  2

This report and the webcast may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties, including statements about the anticipated timing of release of topline results of our clinical trials; the progression of our discovery programs into clinical development; and the business and operations of Cyclerion. We may, in some cases use terms such as "predicts," "believes," "potential," "continue," "anticipates," "estimates," "expects," "plans," "intends," "may," "could," "might," "likely," "will," "should" or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include the risks listed under the heading "Risk Factors" and elsewhere in our 2019 Form 10-K filed on March 12, 2020, and in Cyclerion's subsequent SEC filings, including the Form 10-Q filed on May 4, 2020, including without limitation risks relating to IW-6463. Investors are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements (except as otherwise noted) would speak only as of the respective dates of this report and the webcast, and Cyclerion undertakes no obligation to update these forward-looking statements, except as required by law.

Item 9.01 Financial Statements and Exhibits






(d)



Exhibit No.                                 Description

  99.1          Press Release of Cyclerion Therapeutics, Inc. dated June 18, 2020




  3

© Edgar Online, source Glimpses